Goldman Sachs Global Future Health Care Equity Portfolio Base USD Acc

Equity fund

1 year

Globe

USA

Largest region

Medium

Risk

Annual costs

Morningstar

 

Partial 

Sustainability

Development

Last 5 years

Description

  • The Portfolio seeks long-term capital appreciation by investing primarily in equity securities of companies that are domiciled anywhere in the world which, in the view of the Investment Adviser, have the potential to be beneficiaries of evolving trends in the health care sector, including, but not limited to, the beneficiaries and drivers of advancements in genomics, precision medicine, life extension and robotic surgery.

Investment horizon

  • Goldman Sachs Global Future Health Care Equity Portfolio Base USD Acc is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.

Characteristics

  • Minimum amount
  • Sharpe 3 years
  • Price/NAV

    27 Aug 2025

  • Start date
    29 Sept 2020
  • ISIN
    LU2220395680

Risk

  • Medium (4 of 7)

Morningstar rating

  • The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.

Sustainability

Costs

  • Ongoing costs

    Includes management fees of 1,50 %

  • Platform fee
  • Kickback fee
  • Annual running costs
  • Performance-based fee
  • Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund. Costs for any currency exchanges are not included.

Allocation

  • Stocks 98%
    Interest 2%

Portfolio

Shows the fund's largest investments.

  • Eli Lilly and Co
    9.3%
  • Boston Scientific Corp
    9.0%
  • Abbott Laboratories
    6.3%
  • AbbVie Inc
    5.3%
  • Intuitive Surgical Inc
    4.8%
  • AstraZeneca PLC
    4.6%
  • Insulet Corp
    4.5%
  • UnitedHealth Group Inc
    4.4%
  • Thermo Fisher Scientific Inc
    3.7%
  • Lonza Group Ltd
    3.5%